Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain

Neuroscience

Volumn 154, Issue 3, 2008, Pages 1100-1106

  Wang, Q ^a   Zengin, A ^a   Ying, W ^b   Newell, K A ^a   Wang, P ^d   Yeo, W ^a   Wong, P T H ^c   Yenari, M A ^b   Huang, X F ^a  

^a Graduate School of Medicine   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; hydroxymethylglutaryl coenzyme reductase inhibitors; muscarinic receptors; statins; upregulation

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; PIRENZEPINE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CADAVER; CAUDATE NUCLEUS; CHOLINERGIC SYSTEM; CINGULATE GYRUS; COGNITION; CONTROLLED STUDY; DEGENERATIVE DISEASE; HIPPOCAMPUS; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; UPREGULATION;

ANIMALS; AUTORADIOGRAPHY; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MUSCARINIC ANTAGONISTS; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4; SIMVASTATIN; UP-REGULATION;

EID: 46549089034     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.04.026     Document Type: Article

References (53)

1. Baskin F., Rosenberg R.N., Fang X., Hynan L.S., Moore C.B., Weiner M., and Vega G.L. Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients. Neurology 60 12 (2003) 2006-2007
2. Bymaster F.P., Felder C., Ahmed S., and McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 1 2 (2002) 163-181
3. Bymaster F.P., Felder C.C., Tzavara E., Nomikos G.G., Calligaro D.O., and McKenzie D.L. Muscarinic mechanisms of antipsychotic atypicality. [review]. Prog Neuropsychopharmacol Biol Psychiatry 27 7 (2003) 1125-1143
4. Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., and LaFerla F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49 5 (2006) 671-682
5. Chen J., Zhang Z.G., Li Y., Wang Y., Wang L., Jiang H., Zhang C., Lu M., Katakowski M., Feldkamp C.S., and Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53 6 (2003) 743-751 Erratum in: Ann Neurol 2005;58(5):818
6. Cibickova L., Palicka V., Cibicek N., Cermakova E., Micuda S., Bartosova L., and Jun D. Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiol Res 56 (2007) 765-770
7. Clader J.W., and Wang Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. [review]. Curr Pharm Des 11 26 (2005) 3353-3361
8. Cordle A., and Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci 25 2 (2005) 299-307
9. Darvesh S., Martin E., Walsh R., and Rockwood K. Differential effects of lipid-lowering agents on human cholinesterases. Clin Biochem 37 1 (2004) 42-49
10. Dean B. M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia. Neuropsychopharmacology 29 8 (2004) 1583-1584
11. De Klippel N., Sarre S., Ebinger G., and Michotte Y. Effect of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism: an in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats. Brain Res 630 1-2 (1993) 57-64
12. Flynn D.D., Ferrari-DiLeo G., Mash D.C., and Levey A.I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 64 4 (1995) 1888-1891
13. Flynn D.D., and Mash D.C. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse 14 4 (1993) 283-296
14. Greenberg D.A., and Jin K. From angiogenesis to neuropathology. Nature 438 7070 (2005) 954-959
15. Hao W., Xing-Jun W., Yong-Yao C., Liang Z., Yang L., and Hong-Zhuan C. Up-regulation of M1 muscarinic receptors expressed in CHOm1 cells by panaxynol via cAMP pathway. Neurosci Lett 383 1-2 (2005) 121-126
16. Ifergan I., Wosik K., Cayrol R., Kebir H., Auger C., Bernard M., Bouthillier A., Moumdjian R., Duquette P., and Prat A. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 60 1 (2006) 45-55
17. Jin K., Galvan V., Xie L., Mao X.O., Gorostiza O.F., Bredesen D.E., and Greenberg D.A. Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw, Ind) mice. Proc Natl Acad Sci U S A 101 36 (2004) 13363-13367
18. Jin K., Xie L., Mao X.O., and Greenberg D.A. Alzheimer's disease drugs promote neurogenesis. Brain Res 1085 1 (2006) 183-188
19. Kay G.G., Abou-Donia M.B., Messer Jr. W.S., Murphy D.G., Tsao J.W., and Ouslander J.G. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. [review]. J Am Geriatr Soc 53 12 (2005) 2195-2201
20. Levey A.I., Edmunds S.M., Koliatsos V., Wiley R.G., and Heilman C.J. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 15 5 Pt 2 (1995) 4077-4092
21. Li G., Larson E.B., Sonnen J.A., Shofer J.B., Petrie E.C., Schantz A., Peskind E.R., Raskind M.A., Breitner J.C., and Montine T.J. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69 9 (2007) 878-885
22. Lin P., Li F., Zhang Y.W., Huang H., Tong G., Farquhar M.G., and Xu H. Calnuc binds to Alzheimer's beta-amyloid precursor protein and affects its biogenesis. J Neurochem 100 6 (2007) 1505-1514
23. Lu D., Goussev A., Chen J., Pannu P., Li Y., Mahmood A., and Chopp M. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma 21 1 (2004) 21-32
24. Mok S.W., Thelen K.M., Riemer C., Bamme T., Gültner S., Lütjohann D., and Baier M. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem Biophys Res Commun 348 2 (2006) 697-702
25. Molina-Holgado E., Khorchid A., Liu H.N., and Almazan G. Regulation of muscarinic receptor function in developing oligodendrocytes by agonist exposure. Br J Pharmacol 138 1 (2003) 47-56
26. Mozayan M., and Lee T.J. Statins prevent cholinesterase inhibitor blockade of sympathetic {alpha}7-nAChR-mediated currents in rat superior cervical ganglion neurons. Am J Physiol Heart Circ Physiol 293 3 (2007) H1737-H1744
27. Mrzljak L., Levey A.I., and Goldman-Rakic P.S. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci U S A 90 11 (1993) 5194-5198
28. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., Nakaya N., Nishimoto S., Muranaka M., Yamamoto A., Mizuno K., Ohashi Y., and MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 9542 (2006) 1155-1163
29. Newell K.A., Zavitsanou K., and Huang X.F. Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. J Neurosci Res 85 6 (2007) 1358-1363
30. Newell K.A., Zavitsanou K., Jew S.K., and Huang X.F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31 1 (2007) 225-233
31. Nio J., Besson M.J., and Breton P. Ontogenic distribution of muscarinic receptors and acetylcholinesterase in the rabbit hippocampus. Brain Res Bull 31 6 (1993) 723-732
32. Ovbiagele B., Saver J.L., Starkman S., Kim D., Ali L.K., Jahan R., Duckwiler G.R., Viñuela F., Pineda S., and Liebeskind D.S. Statin enhancement of collateralization in acute stroke. Neurology 68 24 (2007) 2129-2131
33. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1997), Academic Press, San Diego
34. Ravipati G., Aronow W.S., Ahn C., Channamsetty V., and Sekhri V. Incidence of new stroke or new myocardial infarction or death in patients with severe carotid arterial disease treated with and without statins. Am J Cardiol 98 9 (2006) 1170-1171
35. Riekse R.G., Li G., Petrie E.C., Leverenz J.B., Vavrek D., Vuletic S., Albers J.J., Montine T.J., Lee V.M., Lee M., Seubert P., Galasko D., Schellenberg G.D., Hazzard W.R., and Peskind E.R. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 10 4 (2006) 399-406
36. Roensch J., Crisby M., Nordberg A., Xiao Y., Zhang L.J., and Guan Z.Z. Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochem Int 50 6 (2007) 800-806
37. Schoonjans K., Peinado-Onsurbe J., Fruchart J.C., Tailleux A., Fiévet C., and Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett 452 3 (1999) 160-164
38. Selley M.L. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 1037 1-2 (2005) 1-6
39. Smolders I., Bogaert L., Ebinger G., and Michotte Y. Muscarinic modulation of striatal dopamine, glutamate, and GABA release, as measured with in vivo microdialysis. J Neurochem 68 5 (1997) 1942-1948
40. Svedberg M.M., Bednar I., and Nordberg A. Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase. Neuropharmacology 47 4 (2004) 558-571
41. Tigges M., Tigges J., Rees H., Rye D., and Levey A.I. Distribution of muscarinic cholinergic receptor proteins m1 to m4 in area 17 of normal and monocularly deprived rhesus monkeys. J Comp Neurol 388 1 (1997) 130-145
42. Tzavara E.T., Bymaster F.P., Felder C.C., Wade M., Gomeza J., Wess J., McKinzie D.L., and Nomikos G.G. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 8 7 (2003) 673-679
43. Vega G.L., Weiner M.F., Lipton A.M., Von Bergmann K., Lutjohann D., Moore C., and Svetlik D. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 60 4 (2003) 510-515
44. Volpicelli-Daley L.A., Duysen E.G., Lockridge O., and Levey A.I. Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice. Ann Neurol 53 6 (2003) 788-796
45. Wang Q., and Huang X.F. Effects of chronic treatment of olanzapine and haloperidol on peptide YY binding densities in the rat brain. Exp Neurol 209 1 (2008) 261-267
46. Wang Q., Tang X.N., Wang L., Yenari M.A., Ying W., Goh B.C., Lee H.S., Wilder-Smith E.P., and Wong P.T. Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci Lett 408 3 (2006) 189-193
47. Wang Q., Ting W.L., Yang H., and Wong P.T. High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. Br J Pharmacol 144 7 (2005) 933-939
48. Xiu J., Nordberg A., Shan K.R., Yu W.F., Olsson J.M., Nordman T., Mousavi M., and Guan Z.Z. Lovastatin stimulates up-regulation of alpha7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the alpha-form of secreted amyloid precursor protein. J Neurosci Res 82 4 (2005) 531-541
49. Xu H., Wang R., Zhang Y.W., and Zhang X. Estrogen, beta-amyloid metabolism/trafficking, and Alzheimer's disease. Ann N Y Acad Sci 1089 (2006) 324-342
50. Xu M., Mizobe F., Yamamoto T., and Kato T. Differential effects of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats. Brain Res 495 2 (1989) 232-242
51. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 6911 (2002) 78-84
52. Zavitsanou K., Katsifis A., Mattner F., and Huang X.F. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29 3 (2004) 619-625
53. Zhang W., Yamada M., Gomeza J., Basile A.S., and Wess J. Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J Neurosci 22 15 (2002) 6347-6352